Prevalence of Metabolic Syndrome and Affecting Factors among Individuals Aged 30 and over in Balçova District of İzmir

Year 2016, Volume: 33 Issue: 3, 331 - 338, 01.05.2016

Ahmet Soysal Hatice Şimşek Türkan Günay Sinem Doğanay

Abstract

Background: The studies have shown that metabolic syndrome (MetS) leads to an increase twice as much in cardiovascular diseases (CVD) and four times as much in diabetes mellitus (DM) prevalence since the second half of the 20th century. Aims: This study aims to determine and discuss the prevalence of the MetS and co- factors among individuals at the age of 30 and over in Balcova district of İzmir province according to the American National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATP III) and InternationalDiabetes Federation (IDF) criteria. Study Design: Cross-sectional study. Methods: Data obtained from the Balcova Heart Project in İzmir were used in the study. The dependent variable of the study is MetS existence. The independent variables were socio-demographic characteristics (age, gender, education level, and marital status), self-perceived economic status, physical activity, smoking status, healthy nutrition and body mass index (BMI). Results: The prevalence of MetS was 36.9% according to the diagnostic criteria of IDF, while it was 27.4% according to ATP III criteria. According to the both criteria, increasing age, low education, poor economic status perception, physical inactivity, and obesity increase the risk of MetS. Apart from the IDF criteria, being female and a current smoker increase the risk of the MetS in the NCEP-ATP III. Conclusion: Compared to educational studies of MetS as of today, which are community and health-oriented studies, it is challenging that the prevalence of MetS was found to be high for both criteria in our study. Therefore, in particular, primary health care doctors must be prompted to protect the public against DM and CVD in particular.

Keywords

IDF criteria, metabolic syndrome, NCEP-ATP III criteria, prevalence

References

• 1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. [CrossRef] 2. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121- 31. [CrossRef]
• 3. Gedik O. Metabolik sendromun tanımı ve tanı kriterleri. Klinik Aktüel Tıp, 2005; Metabolik sendrom özel sayısı, 5:1-5.
• 4. Alberti KG, Zimmet PZ. Provisional report of a WHO consultation Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis. Diabet Med 1998;15:539-53. [CrossRef]
• 5. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabet Med 1999;16:442-3. [CrossRef]
• 6. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3142-421.
• 7. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Internatioanl Diabetes Federation 2006 Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
• 8. Soysal A, Demiral Y, Soysal D, Uçku R, Köseoğlu M, Aksakoğlu G. The prevalence of metabolic syndrome among young adults in Izmir, Turkey. Anadolu Kardiyol Derg 2005;5:196-201.
• 9. Santos AC, Ebrahim S, Barros H. Gender, socio-economic status and metabolic syndrome in middle-aged and old adults. BMC Public Health 2008;8:62. [CrossRef]
• 10. Hoang CK, Ghandeari H, Lopez VA, Barboza MG, Wong ND. Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S. Diabetes Care 2008;31:1405-9. [CrossRef]
• 11. Tanyolaç S, Çıkım AS, Azezli AD, Orhan Y. Correlation between educational status and cardiovascular risk factors in an overweight and obese Turkish female population. Anadolu Kardiol Derg 2008;8:336-41.
• 12. Onat A, Sarısoy V. Halkımızda koroner hastalığın baş suçlusu metabolik sendrom: sıklığı, unsurları, koroner risk ile ilişkisi ve yüksek risk kriterleri. Türk Kardiyoloji Dern Arş 2002;30:8-15.
• 13. Ergör G, Soysal A, Sözmen K, Ünal B, Uçku R, Kılıç B, et al. Balçova Heart Study: rationale and methodology of Turkish cohort. Int J Public Health 2012;535-42. [CrossRef]
• 14. Athyros VG, Ganotakis ES, Bathianaki M, Mönedas I, Goudevenos IA, Papageorgiou AA, et al. Awareness, treatment and control of the metabolic syndrome and its components: A Multicentre Greek Study. Hellenic J Cardiol 2005;46:380-6.
• 15. Santos AC, Barros H. Impact of metabolic syndrome definitions on prevalence estimates: A study in a Portuguese Community. Diab Vasc Dis Res 2007;4:320-7. [CrossRef]
• 16. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jöcke KH. Impact of the metabolic syndrome in primary healthcare: The German metabolic and cardiovascular risk project (GEMCAS). Cardiovasc Diabetol 2007;6:22. [CrossRef]
• 17. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Agespecific prevalence of the metabolic syndrome defined by the national cholesterol education program: The Norwegian HUNT 2 Study. BMC Public Health 2007;7:220. [CrossRef]
• 18. Matei C, Pop I, Jurgut R, Suceveanu M, Predescu D, Nechita E, et al. ROmanian multicentric study of the prevalence of MEtabolic Syndrome-ROMES. Hellenic J Cardiol 2008;49:303-9.